UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/19.03.25 | Real-time Bid/Ask 01:00:02 23/05/2024 pm IST | ||
| 0.8 EUR / 1.02 EUR | 0.00% |
|
| Current month | +127.50% | ||
| 1 month | +30.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 23/24/23 | 0.77 | -15.38% |
| 22/24/22 | 0.91 | +4.60% |
| 21/24/21 | 0.87 | -14.71% |
| 20/24/20 | 1.02 | +10.87% |
| 17/24/17 | 0.92 | +10.84% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 12:56 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD441Z |
| ISIN | DE000HD441Z2 |
| Date issued | 25/03/2024 |
| Strike | 600 $ |
| Maturity | 19/03/2025 (301 Days) |
| Parity | 10 : 1 |
| Emission price | 0.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.15 € |
|---|---|
| Lowest since issue | 0.32 € |
| Spread | 0.27 € |
| Spread % | 26.21% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
447.5
USD
Average target price
462.8
USD
Spread / Average Target
+3.41%
- Stock Market
- Warrants
- Warrant
